Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2014; 20(6): 1594-1601
Published online Feb 14, 2014. doi: 10.3748/wjg.v20.i6.1594
Published online Feb 14, 2014. doi: 10.3748/wjg.v20.i6.1594
Table 4 Adverse events occurring in more than one patient
| rSK (n = 110) | Phenylephrine (n = 110) | |
| Total subjects with adverse events | 19 (17.3) | 30 (27.3) |
| Events | ||
| Local burning sensation | 3 (2.7) | 11 (10.0) |
| Local pricking sensation | 4 (3.6) | 9 (8.2) |
| Rectal bleeding | 5 (4.5) | 4 (3.6) |
| Anal pruritus | 3 (2.7) | 5 (4.5) |
| Diarrhea | 4 (3.6) | 0 |
| Headache | 1 (0.9) | 3 (2.7) |
| Anal pain | 3 (2.7) | 1 (0.9) |
| Local heat sensation | 0 | 2 (1.8) |
-
Citation: Hernández-Bernal F, Castellanos-Sierra G, Valenzuela-Silva CM, Catasús-Álvarez KM, Valle-Cabrera R, Aguilera-Barreto A, Investigators PALSTT3GO. Recombinant streptokinase
vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3). World J Gastroenterol 2014; 20(6): 1594-1601 - URL: https://www.wjgnet.com/1007-9327/full/v20/i6/1594.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i6.1594